UCB U.S. News | UCB

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Categories

Archives

2026
- June
- May
- April
- March
- February
2025
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2024
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2023
- December
- November
- October
- September
- August
- July
- June
- April
- March
- February
- January

Apr

17

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Read More

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Read More

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Read More

Choose a Country